NewEdge Advisors’s Rocket Pharmaceuticals RCKT Stock Holding History

NewEdge Advisors’s Portfolio RCKT Stock Details RCKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.39K	Hold	700	–	–	﹤0.01%	3885
2026 Q1	$2.51K	Hold	700	–	–	﹤0.01%	3760
2025 Q4	$2.46K	Hold	700	–	–	﹤0.01%	3845
2025 Q3	$2.28K	Hold	700	–	–	﹤0.01%	3752
2025 Q2	$1.72K	Buy	700 +100	+17%	+$507	﹤0.01%	3647
2025 Q1	$4K	Buy	+600	New	+$5.93K	﹤0.01%	3357

Other funds holding RCKT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

MAM

Monaco Asset Management Monaco $1.26B AUM 60.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

NewEdge Advisors's RCKT Position: Q2 2026 in Review

NewEdge Advisors held its Rocket Pharmaceuticals (RCKT) position steady in Q2 2026 at 700 shares worth $2.39K. The position accounts for ﹤0.01% of the portfolio, ranked #3885.

NewEdge Advisors first reported a position in RCKT in Q1 2025 and has held it in 6 quarters since. The position peaked at $4K in Q1 2025. 116 funds tracked by Wall St. Rank hold RCKT as of Q2 2026.

NewEdge Advisors held 700 shares of Rocket Pharmaceuticals worth $2.39K as of Q2 2026.
NewEdge Advisors left its Rocket Pharmaceuticals share count unchanged in Q2 2026.
Rocket Pharmaceuticals made up ﹤0.01% of NewEdge Advisors's portfolio in Q2 2026, its #3885 holding.
NewEdge Advisors first reported a position in Rocket Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
NewEdge Advisors's Rocket Pharmaceuticals position peaked at $4K in Q1 2025.
116 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2026.

Based on NewEdge Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.